Remibrutinib Phase 3 MS success drives Novartis premarket surge

 

Remibrutinib Phase 3 MS success drives Novartis 4.64% premarket surge

• Novartis announced positive REMODEL-1/2 Phase 3 results early today for oral BTK inhibitor remibrutinib in relapsing multiple sclerosis (RMS).
• Drug met primary endpoint with significant reduction in annualized relapse rate versus Sanofi's Aubagio (teriflunomide).
• Remibrutinib showed superiority on key secondaries including MRI lesion reduction and slowing disability progression.
• Favorable safety profile reported with no new or increased liver safety signals observed.
• Novartis plans to file for global regulatory approvals based on the strong data readout.
• News matches timing of premarket move; viewed as key pipeline asset with substantial peak sales potential.

https://finviz.com/stock?t=NVS&p=d